Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transactions
SEC Form 4 Filing
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports the disposal of shares to cover tax obligations arising from vesting restricted stock units.
Summary
- On June 1, 2024, Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, disposed of 714 shares of common stock at a price of $20.65.
- Additionally, Gao Hanlin disposed of 268 shares of common stock, also at $20.65 on the same date.
- These transactions were to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 28, 2022.
- Following these transactions, Gao Hanlin beneficially owns 926,388 shares of Fulgent Genetics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a routine filing related to insider transactions, specifically the disposal of shares to cover tax obligations arising from vested equity compensation. Such filings are common and provide transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
- Similar transactions are regularly reported by executives at comparable companies like Exact Sciences, Invitae, and Myriad Genetics.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to tax obligations and do not indicate a change in the executive's overall confidence in the company.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of grant for the restricted stock units that led to the tax obligations. |
| March 2, 2022 | Original Form 4 filing date for the restricted stock units grant. |
| June 1, 2024 | Date of the stock disposal transactions. |
| June 4, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.